This the final MOASC Lung Cancer Webinar of 2023 included introductions by moderator, Dr. Husain, UCSD and discussants Dr. Garon, UCLA and Dr. Neal, Stanford. This webinar wraps up the year-long discussion of ADC’s, Tarlatamab, LAG3, TILs, and Novel Targeted Therapies, i.e., KRAS, ROS1, MET, EGFR.

Sponsored in part by AstraZeneca and Daiichi Sankyo.